Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 633

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 633
---
 funding cap (i.e. $900,000plus$694,503, or $1,594,503, as of the date of the CTF Agreement’s execution). The Existing Advances funded prior to the execution of both the CTF Agreement as well as the Merger Agreement represent advances already made by TuHURA to Kineta in connection with the exclusivity agreement and are included as a credit against the cash component of the Merger Consideration to be paid to Kineta stockholders in the Mergers. Any future Advances made under the CTF Agreement will not count towards the Merger Consideration. As of September 30, 2024, one Existing Advance had been made for $75,572. Through the date of this unaudited pro forma condensed combined financial information, the total subsequent advances that have been made aggregate to $618,931 (reflected within Pro Forma AdjustmentAin Note 4 of the notes to the unaudited pro forma condensed combined financial information).The Concurrent InvestmentIn connection with the Merger Agreement and as a condition precedent to the completion of the Mergers, the Company plans to enter into subscription agreements with interested investors to purchase TuHURA Common Stock for net proceeds of at least $35 million. TuHURA has not currently executed any subscription agreement in connection with the contemplated Concurrent Investment. The Concurrent Investment is presented in the unaudited pro forma condensed combined financial statement as contemplated since it is a condition of closing of the Mergers. The Concurrent Investment is currently estimated for purposes of these pro formas to be the issuance of 6,518,565 shares of TuHURA Common Stock at a purchase price of approximately $5.7528 per share (equal to the TuHURA Share Value) and with $2.5 million of net equity issuance costs (the Concurrent Investment is reflected within Pro Forma AdjustmentCin Note 4 of the notes to the unaudited pro forma condensed combined financial information).409
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF SEPTEMBER 30, 2024 (in thousands)

| ASSETS                                         
 Current assets:                                |     | Legacy       
 TuHURA       
 (Historical) |        |     | Kintara      
 (Historical) |       |     | Additional 
 Financings |   |     | Pro Forma   
 Adjustments |         |   |     |    |     | TuHURA       
 Biosciences, 
 Inc.